Skip to main content
< Back
About
About the conference
Latest updates
Organisers & Partners
App
Press room
Programme 19
Full programme
Tracks
Speakers 19
Keynote speakers
All speakers
Side events 19
Venue 19
About the venue
Location
Rooms
Subscribe
Overdose
Sessions
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
New psychoactive substances
Health consequences
Overdose — Treatment: medical/pharmacological
Wednesday, 23 October
10:50
Understanding and improving health and social outcomes
10:50
to
12:20
Networking zone 3 (N3)
Sanna Rönkä
Opioid-related deaths in Europe and Australia
10:50
to
12:20
Main stage
Eilish Gilvarry
13:20
Insights on opioid substitution treatment, prison post-release mortality, and cross indicator analysis
Improving the validity of drug-related deaths data for policy making
13:20
to
14:50
Central square 1 (C1)
Isabelle Giraudon
15:00
Improving responses to opioid-related harm
15:00
to
16:30
Central square 3 (C3)
Steve Gust
Thursday, 24 October
10:50
Understanding behaviours, risks and harms
10:50
to
12:20
Networking zone 3 (N3)
Xavier Majó
13:20
Cannabis — risks and responses
13:20
to
14:50
Networking zone 4 (N4)
Jennifer Price
Evidence to guide future practice and policy
Enhancing hepatitis C treatment outcomes among people who use drugs
13:20
to
14:50
Insights zone 1 (I1)
Catharina Matheï
Adrian Dunlop
Reducing drug-related deaths
13:20
to
14:50
Central square 2 (C2)
Catherine Comiskey
The Reitox network poster session
13:20
to
14:50
Guided poster tours room
Nadine Berndt
15:00
Take-home naloxone — its role in preventing opioid-related deaths in Europe
15:00
to
16:30
Insights zone 3 (I3)
Dagmar Hedrich
Sir John Strang
Opioid-related deaths and other harms: current and emerging lessons - SSA poster session
15:00
to
16:30
Guided poster tours room
Sarah Welch
18:30
Opioids — current and emerging lessons
18:30
to
19:30
Networking zone 4 (N4)
Roumen Sedefov
Friday, 25 October
10:45
Opioid-related deaths: learning from epidemiological studies
10:45
to
12:15
Insights zone 3 (I3)
Sarah Welch
Presentations
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Wednesday, 23 October
11:00
Short communication
Portuguese gender-sensitive harm reduction services: bridging the gap
11:00
to
11:10
Networking zone 3 (N3)
Oral presentation
Drug deaths in Scotland: inevitable or preventable?
11:00
to
11:15
Main stage
Roy Robertson
11:10
Short communication
A change in the prescribing practice of prebagalin that has had a direct negative effect on drug-induced deaths in Ireland
11:10
to
11:20
Networking zone 3 (N3)
Ena Lynn
11:15
Oral presentation
Cause-specific excess mortality in people who use opioids illicitly: systematic review and meta-analysis
11:15
to
11:30
Main stage
Sarah Larney
11:30
Short communication
Performance enhancing drugs. Results from a Belgian survey on PED use among workers
11:30
to
11:40
Networking zone 3 (N3)
Marie-Claire Lambrechts
Oral presentation
Prevention of drug related mortality: the role of opioid agonist treatment
11:30
to
12:00
Main stage
Matthew Hickman
Louisa Degenhardt
11:40
Short communication
Drug and alcohol treatment: how much does it cost in Europe?
11:40
to
11:50
Networking zone 3 (N3)
Claudia Costa Storti
11:50
Short communication
Young people's exposure to gambling advertisements: a mixed methods study in Australia.
11:50
to
12:00
Networking zone 3 (N3)
Hannah Pitt
12:00
Short communication
Street Work Nursing as an innovative strategy in the care for dually diagnosed individuals: reflections on a pilot study
12:00
to
12:10
Networking zone 3 (N3)
Ilse Goethals
Oral presentation
Discussant
12:00
to
12:20
Main stage
Edward Nunes
12:10
Short communication
Dissuasion, the effectiveness of the intervention and good practices
12:10
to
12:20
Networking zone 3 (N3)
Américo Gegaloto
13:20
Oral presentation
Epidemiology of drug-related deaths in Europe, and focus in two countries on underestimation and possible corrections of the reported number of deaths
13:20
to
14:50
Central square 1 (C1)
Isabelle Giraudon
Oral presentation
Comparison between drug-related deaths data from special and general mortality registers in Austria. Implications for monitoring and policy making
13:20
to
14:50
Central square 1 (C1)
Judith Anzenberger
Oral presentation
Mortality during and after opioid substitution treatment in Austria 2002 to 2016
13:20
to
14:50
Central square 1 (C1)
Martin Busch
Oral presentation
Prison post-release mortality among drug-users in Lithuania
13:20
to
14:50
Central square 1 (C1)
Lina Jurgelaitiene
15:10
Oral presentation
The evolving opioid overdose crisis and the rising role of methamphetamine
15:10
to
15:25
Central square 3 (C3)
Christopher Jones
15:25
Oral presentation
Examination of emerging adults with opioid use disorders
15:25
to
15:40
Central square 3 (C3)
Holly Hills
15:40
Oral presentation
Recent non-fatal opioid overdose: the effects of health service utilisation, alcohol and other drug use and demographic factors
15:40
to
15:55
Central square 3 (C3)
Penelope Hill
15:55
Oral presentation
In utero opioid exposure and risk of infections in childhood: a multinational Nordic cohort study
15:55
to
16:10
Central square 3 (C3)
Marte Handal
16:10
Oral presentation
Reducing inappropriate use of prescription opioids in hospital patients
16:10
to
16:25
Central square 3 (C3)
Erin Winstanley
Thursday, 24 October
11:00
Short communication
Neuropsychological functioning, psychopathology, and parenting behaviours in the context of substance use disorders: which are the implications for treatment?
11:00
to
11:10
Networking zone 3 (N3)
Alessio Porreca
11:10
Short communication
Childhood adversity within adolescent friendship groups: Implications for subsequent substance use disorders
11:10
to
11:20
Networking zone 3 (N3)
Lauren Bishop
11:20
Short communication
Cause-specific hospitalisation and death in a cohort of people who use heroin and crack cocaine in London, England: the importance of non-communicable diseases, skin infections, head injuries and dental caries
11:20
to
11:40
Networking zone 3 (N3)
Dan Lewer
11:30
Short communication
Yearning to be better than good –Lithuanian students of medicine use of cognitive enhancers among
11:30
to
11:40
Networking zone 3 (N3)
Aiste Lengvenyte
11:40
Short communication
New issues regarding drug-related deaths: combined suicide
11:40
to
11:50
Networking zone 3 (N3)
Mateja Jandl
11:50
Short communication
Women and HIV in prison setting: data from the Italian ROSE network
11:50
to
12:00
Networking zone 3 (N3)
12:00
Short communication
Non-national clients in Belgian drug treatment: different profile characteristics compared to Belgian clients
12:00
to
12:10
Networking zone 3 (N3)
Charlotte De Kock
13:20
Poster
Trends on the Dutch drug market identified by DIMS in 2018
13:20
to
14:50
Guided poster tours room
Laura Smit-Rigter
Poster
Gendered sources of drug supply for recreational drug users in the European Web Survey on Drugs
13:20
to
14:50
Guided poster tours room
Michael Vuolo
Poster
Trends in primary substance mentioned by patients entering treatment for illicit substance use in Belgium between 2012 and 2018
13:20
to
14:50
Guided poster tours room
Antoine Jérôme
Poster
Criminal reactions and reduction of crime and drug use in drug-using offenders
13:20
to
14:50
Guided poster tours room
Olga Souza Cruz
Poster
Fatal traffic accidents in connection to driving under the influence of psychoactive substances
13:20
to
14:50
Guided poster tours room
Ada Hocevar Grom
Poster
HIV infection in drug users in harm reduction structures
13:20
to
14:50
Guided poster tours room
Isabel Ponte
Poster
Drug-related deaths and mortality in Europe
13:20
to
14:50
Guided poster tours room
Federica Mathis
Poster
Demand for drug treatment in Europe: the Treatment Demand indicator (TDI)
13:20
to
14:50
Guided poster tours room
Linda Montanari
Poster
Non-medical prescription drug use among Estonian adults
13:20
to
14:50
Guided poster tours room
Sigrid Vorobjov
Poster
Monitoring drug-related infectious diseases in Europe
13:20
to
14:50
Guided poster tours room
Thomas Seyler
Poster
Estimating the number of people who inject drugs (PWID) in Europe
13:20
to
14:50
Guided poster tours room
Thomas Seyler
13:30
Short communication
Acute effects of cannabinoids on addiction endophenotypes are moderated by genes encoding the CNR1 receptor and FAAH enzyme
13:30
to
13:40
Networking zone 4 (N4)
Chandni Hindocha
Oral presentation
Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England
13:30
to
13:45
Central square 2 (C2)
John Marsden
Oral presentation
HepCATT (Hepatitis C Assessment to Treatment Trial) in primary care: a cluster RCT of whether a complex intervention based on risk prediction algorithm tool and education can increase testing and diagnosis of HCV in primary care
13:30
to
13:45
Insights zone 1 (I1)
Matthew Hickman
13:40
Short communication
Psychological aspects of cannabis use disorder: a review of the theory and implications for psychotherapy
13:40
to
13:50
Networking zone 4 (N4)
Daniel Feingold
13:45
Oral presentation
Results of mortality cohort study of problem drug users in Poland.
13:45
to
14:00
Central square 2 (C2)
Janusz Sieroslawski
Oral presentation
Real-life effectiveness of direct-acting antiviral treatment among chronic hepatitis C infected opioid substituted patients in Germany
13:45
to
14:00
Insights zone 1 (I1)
Bernd Schulte
13:50
Short communication
Intention to reduce cannabis use and help-seeking attitudes in Dutch frequent cannabis users.
13:50
to
14:00
Networking zone 4 (N4)
Marleen Olthof
14:00
Short communication
Perceptions of effectiveness and believability of pictorial and text-only health warning labels for cannabis products among Canadian youth.
14:00
to
14:10
Networking zone 4 (N4)
Cesar Leos-Toro
Oral presentation
Hepatitis C Virus (HCV) elimination and the opioid crisis: joint problems, joint solution – results of a pilot programme
14:00
to
14:15
Insights zone 1 (I1)
Brian Conway
Oral presentation
Nasal naloxone for overdose prevention in Norway: results from the first four years
14:00
to
14:15
Central square 2 (C2)
Oral presentation
Nasal naloxone for overdose prevention in Norway: results from the first four years
14:00
to
14:15
Central square 2 (C2)
Desiree Eide
14:10
Short communication
Cannabis use in early adulthood and later prescription of antipsychotics, mood stabilisers, antidepressants and anxiolytics.
14:10
to
14:20
Networking zone 4 (N4)
Eline Rognli
14:15
Oral presentation
Incidence and predictors of drug overdoses among a cohort of patients treated for substance use disorder
14:15
to
14:30
Central square 2 (C2)
Birgitte Thylstrup
Oral presentation
Service Integration: accessing HCV treatment for homeless PWIDs/ex-PWIDs attending community OST
14:15
to
14:30
Insights zone 1 (I1)
Tina McHugh
14:20
Short communication
Have chronic cannabis consumers developed tolerance to the residual effects of recent cannabis use?
14:20
to
14:30
Networking zone 4 (N4)
Raimondo Bruno
14:30
Short communication
Sociodemographic and educational characteristics of cannabis users attending outpatient treatment centres: implications for psychoeducational intervention
14:30
to
14:40
Networking zone 4 (N4)
Samuel Rueda
Oral presentation
MDMA-related deaths in Australia
14:30
to
14:45
Central square 2 (C2)
Amanda Roxburgh
Oral presentation
The cost-effectiveness of an HCV outreach intervention for at risk populations in London
14:30
to
14:45
Insights zone 1 (I1)
Zoe Ward
Oral presentation
Reduction in the population prevalence of chronic HCV among people who inject drugs associated with major scale-up of direct-acting antiviral therapy in community drug services: real world data
14:30
to
14:45
Insights zone 1 (I1)
Norah Palmateer
14:40
Short communication
Can cannabis use cause death in humans ?
14:40
to
14:50
Networking zone 4 (N4)
Mateja Jandl
15:00
Poster
Dosing of naloxone in opioid overdose outside of hospital. Observational data 2014 -18 in Oslo, Norway
15:00
to
16:30
Guided poster tours room
Ida Tylleskär
Poster
Increasing trend and differential patterns of opioids prescribing by patient characteristics in primary care in Belgium: a registry-based study
15:00
to
16:30
Guided poster tours room
Catharina Matheï
Poster
Patterns in analgesic opioids use in Germany and France: improved pain management and risks of misuse
15:00
to
16:30
Guided poster tours room
Jessica Neicun
Poster
Barriers to establishing take-home naloxone programmes
15:00
to
16:30
Guided poster tours room
Sibella Hare Breidahl
Poster
Patient characteristics and expected needs: an opioid substitution programme findings
15:00
to
16:30
Guided poster tours room
Catarina Oliveira
Poster
Benzodiazepine use among patients in opioid substituttion treatment: a cross sectional study
15:00
to
16:30
Guided poster tours room
Catarina Oliveira
Poster
Hospitalisation of children after prenatal exposure to Methadone and Buprenorphine: national registry study from Czechia
15:00
to
16:30
Guided poster tours room
Blanka Nechanská
Poster
Uncovering trajectories of satisfaction with injectable opioid agonist treatment for severe opioid use disorder
15:00
to
16:30
Guided poster tours room
Kirsten Marchand
Poster
Predicting pain intensity following discontinuation of long-term opioid therapy among patients with and without substance use disorders
15:00
to
16:30
Guided poster tours room
Crystal Smith
Poster
Addressing the opioid crisis: engagement in multidisciplinary care
15:00
to
16:30
Guided poster tours room
Tianna Magel
Poster
Comparing rates and characteristics of harms across different pharmaceutical opioids: an examination of Australian ambulance attendances 2013-2018
15:00
to
16:30
Guided poster tours room
Tina Lam
15:10
Oral presentation
Epidemiology of drug-related deaths in Europe, new trends in opioid-related deaths
15:10
to
15:25
Insights zone 3 (I3)
Isabelle Giraudon
15:25
Oral presentation
Take-home naloxone programmes: history and perspectives
15:25
to
15:40
Insights zone 3 (I3)
Sir John Strang
Sibella Hare Breidahl
15:40
Oral presentation
A national DRD policy and the role of take-home naloxone within it
15:40
to
15:55
Insights zone 3 (I3)
Thomas Clausen
15:55
Oral presentation
Fentanyl overdose deaths emergency and response in Estonia
15:55
to
16:10
Insights zone 3 (I3)
Katri Abel-Ollo
16:10
Oral presentation
Reducing drug-related deaths in Europe: a systemic perspective with focus on take-home naloxone
16:10
to
16:25
Insights zone 3 (I3)
Dagmar Hedrich
18:40
Short communication
Opioid-related problems in Baltic States and Poland: has the turning point come?
18:40
to
18:50
Networking zone 4 (N4)
Katri Abel-Ollo
18:50
Short communication
Estonia’s fentanyl battle: time to scale-up overdose prevention strategy?
18:50
to
19:00
Networking zone 4 (N4)
Sibella Hare Breidahl
19:00
Short communication
Assessment of possibilities for raising the quality of health care provided to opioid users by increasing access to substitution treatment
19:00
to
19:10
Networking zone 4 (N4)
Boguslawa Bukowska
19:10
Short communication
Rising incidence of ageing opioid users within the EU wide treatment
19:10
to
19:20
Networking zone 4 (N4)
Anne Marie Carew
19:20
Short communication
The neglected public health problem of opioid use among offenders - why we have failed and where we can improve.
19:20
to
19:30
Networking zone 4 (N4)
Friday, 25 October
10:55
Oral presentation
Overdose deaths in people prescribed opioids for chronic non-cancer pain: Systematic review and meta-analysis
10:55
to
11:10
Insights zone 3 (I3)
Sarah Larney
11:10
Oral presentation
Hidden aspects of the opioid crisis: what factors are driving ageing trends among those using opioid drugs?
11:10
to
11:25
Insights zone 3 (I3)
Anne Marie Carew
11:25
Oral presentation
Comparing rates and characteristics of harms across different pharmaceutical opioids: an examination of Australian ambulance attendances 2013-2018.
11:25
to
11:40
Insights zone 3 (I3)
Tina Lam
11:40
Oral presentation
Causes of death among patients in opioid maintenance treatment in Norway
11:40
to
11:55
Insights zone 3 (I3)
Anne Berit Bech
11:55
Oral presentation
Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs
11:55
to
12:10
Insights zone 3 (I3)
Kirsten Trayner